Episcleral Brachytherapy for the Treatment of Wet AMD

Status unconfirmed · Not applicable

Conditions studied: Macular Degeneration, Choroidal Neovascularization

In brief

This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the follow-up period.

Key facts

Study ID

NCT02988895

Run by

Salutaris Medical Devices, Inc.

People needed

11

Starts

2017-08-01

Expected to finish

2025-05-01

Last updated by the study team

2023-08-30

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of active CNV or PCV due to nAMD
• Poor or non-responsive to FDA approved intravitreal anti-VEGF therapy for nAMD
• BCVA 20/63 or worse Snellen equivalent in the study eye
• Ability to understand nature/purpose of trial and to provide informed consent
• Ability to undergo diagnostic tests and surgical interventions
• Ability to follow instructions and complete the trial including all scheduled visits and follow-up

You may not qualify if…

• Neovascularization other than due to AMD
• Sub-foveal lesion hemorrhage obscuring >50% of lesion
• Targeted neovascular lesion with greatest linear dimension >3750 microns or <1000 microns as determined by angiography
• Presence of subretinal fibrosis, including disciform scar, or retinal pigment epithelial (RPE) atrophy that is extensive or foveal threatening in the study eye
• An existing retinal pigment epithelial (RPE) tear
• Previous treatment (excluding vitamins) for nAMD in the study eye other than anti-VEGF therapy in the last 6 months
• A change in anti-VEGF agent in the previous two administrations
• Anticipate a change to the anti-VEGF agent during the conduct of the study
• Other clinically significant ocular co-morbidity including, but not limited to, glaucoma, optic neuropathy of any cause, maculopathy / retinopathy of any cause other than nAMD, scleritis, enophthalmos, microphthalmia, or other co-morbidities that in the investigator's opinion could require medical or surgical intervention to prevent or treat visual loss or media opacity that might result from that condition (i.e. severe cataracts).
• Previous intraocular surgery in study eye other than for uncomplicated phacoemulsification cataract extraction
• High myopia indicated by a history of refractive error of - 6D or greater (spherical equivalent), demonstrated myopic degeneration, or axial length of >26.5mm.
• Subjects with orbital structural abnormalities, such as small (axial length <21 mm), deep set globes or other globe dystopias that, in the investigator's clinical judgment, would require a change in the angle of insertion or increase the risk of structural damage from retrobulbar anesthesia, sub-Tenon's anesthesia, or retrobulbar device positioning.
• Media opacity sufficient to preclude adequate fundoscopy, OCT, or angiography
• Uncontrolled systemic diseases (e.g. controlled hypertension is acceptable)
• Type I or type II diabetes mellitus
• Any previous therapeutic radiation to the head or neck or other areas that may have resulted in a radiation dose to the retina.
• On anticoagulation or dual anti-platelet therapy with abnormal coagulation panel results.
• Patient unsuitable for IV or local anesthesia
• Any contraindication to anti-VEGF, fluorescein, indocyanine green, topical and local anesthetics, topical antiseptics, or topical antibiotics to be used during the study
• Active ocular or periocular infection or intraocular inflammation
• Fellow eye with a BCVA of 20/63 Snellen Equivalent or worse, with advanced AMD (neovascular or non-exudative AMD with foveal geographic atrophy), or other vision threatening disease that is not eligible for vision restoring treatment (i.e. inoperable cataracts).
• Fellow eye is receiving anti-VEGF therapy
• Have received any investigational treatment for any indication in the previous 30 days
• Any condition which, in the investigators' opinion, would conflict or otherwise prevent the subject from complying with the required procedures, schedule or other study conduct

Where it is running

• Retina Consultants of Hawaii — ‘Aiea, Hawaii, United States
• University Retina — Oak Forest, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.